| (Values in U.S. Thousands) | May, 2026 | Feb, 2026 | Nov, 2025 | Aug, 2025 | May, 2025 |
| Sales | 21,890 | 24,290 | 18,420 | 17,460 | 20,360 |
| Sales Growth | -9.88% | +31.87% | +5.50% | -14.24% | -9.23% |
| Net Income | 3,580 | 4,540 | 680 | -680 | -67,320 |
| Net Income Growth | -21.15% | +567.65% | +200.00% | +98.99% | -2,292.83% |
Simulations Plus Inc (SLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
Fiscal Year End Date: 08/31